Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival.

de Jong Y, Bennani F, van Oosterwijk JG, Alberti G, Baranski Z, Wijers-Koster P, Venneker S, Briaire-de Bruij IH, van de Akker BE, Baelde H, Cleton-Jansen AM, van de Water B, Danen EHJ, Bovée JVMG.

J Bone Oncol. 2019 Nov 17;19:100268. doi: 10.1016/j.jbo.2019.100268. eCollection 2019 Dec.

2.

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status.

Venneker S, Kruisselbrink AB, Briaire-de Bruijn IH, de Jong Y, van Wijnen AJ, Danen EHJ, Bovée JVMG.

Cancers (Basel). 2019 Dec 2;11(12). pii: E1918. doi: 10.3390/cancers11121918.

3.

Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma.

Venneker S, Szuhai K, Hogendoorn PCW, Bovée JVMG.

Virchows Arch. 2020 Jan;476(1):135-146. doi: 10.1007/s00428-019-02699-2. Epub 2019 Nov 14. Review.

PMID:
31728625
4.

Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes.

de Jong Y, Ingola M, Briaire-de Bruijn IH, Kruisselbrink AB, Venneker S, Palubeckaite I, Heijs BPAM, Cleton-Jansen AM, Haas RLM, Bovée JVMG.

Clin Sarcoma Res. 2019 May 28;9:9. doi: 10.1186/s13569-019-0119-0. eCollection 2019.

Supplemental Content

Loading ...
Support Center